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ABSTRACT 
Nearly 40% of drugs coming to the market nowadays are having poor solvency related issues and 70% molecules in the discovery pipeline are in 
effect fundamentally insoluble in water. Nanocrystals is an unmistakable instrument to tackle the issue identified with poor fluid solvency and helps 
in improving the bioavailability of various drugs as presented in the literature. The particle size reduction came about into the temperamental 
nanocrystalline system and the phenomenon of ostawald ripening happens. These techniques are preparing to the improvement of nanosized 
objects, which can play out multiple technological tasks. There are a few couples of noteworthy benefits of nanocrystal formulations, for example, 
upgrade oral bioavailability, improved dose proportionality, reduced food effects, appropriateness for administration by all routes and probability 
of sterile filtration because of diminished particle size range. One of the most adequate preferences of nanocrystals is their wide scope of utilization, 
for example, ophthalmic delivery, oral delivery, transdermal delivery, pulmonary delivery, intravenous delivery and targeted delivery, especially for 
tumour and brain. The increment in the commercial value of nanocrystals just as the measure of nanocrystal products in the market is picking up 
more of attention to be utilized as a strategy so as to get commercial advantages. In this paper, a brief and accurate precis of nanosuspension is 
stated with a specific spotlight on nanosuspension preparation methodologies, benefits and few major applications of nanosuspensions.  
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INTRODUCTION 
Nanotechnology has prompted the rise of another field called 
nanomedicine, which includes the utilization of nanotechnology in 
drug development, improves and offers many all the more energizing 
guarantees of new diagnoses and cures [1]. A newer approach for drug 
delivery for poorly water-soluble compounds has gained lot of 
attention. Where in the drug is presented in the form of nanometer-
sized particles/crystals that can be dispersed in a colloidal solution by 
having a stabilizer on the surface of nanoparticles. Nano sizing alludes 
to the way toward diminishing the size of active pharmaceutical 
ingredient (API) to the submicron level. Nanosuspensions are aqueous 
dispersions comprising of a blend of API and stabilizers, for example, 
surfactant or polymer in water. These stabilizers help in avoiding the 
clump of nanoparticles and keep them separate from one another by 
giving electrostatic/steric repulsion on the surface of nanoparticles. 
Nanotechnology is characterized as the Science and Engineering done 
in the nanoscale that is 10-9m2
Nanosuspensions have been prescribed as an all-inclusive delivery 
approach for orally administered drug particles that fall into BCS class 
II and class IV category of drugs [4]. Butler and Dressman proposed 
the developability classification system (DCS) as a way to divide 
compounds in a more biorelevant way [5]. As per the DCS, which 
shows contrasts between dissolution rate-limited and solubility 
limited compounds, the intrinsic solubility and the related intra-
luminal drug concentration for compounds comes under class II and IV 
are too low to even consider achieving adequate flux over the 
epithelial membrane. Subsequently, complexation or formulation 
approaches lean on solid-state modifications that might be best 
appeared differently in relation to nanocrystals for compounds that 
comes under DCS Class II b and IV [6, 7]. Nowadays, the new chemical 
entities coming out of discovery laboratories in the pharmaceutical 
industry habitually have low water dissolvability because of the high 
throughput screening process [8, 9]. Various formulation techniques 
have been created to address the low fluid solvency of pharmaceutical 
compounds [10]. Since, particle size reduction (i.e., via micronization) 
is a most usual technique that has been utilized as a means for up-
gradation of the absorption of least dissolvable drugs via oral route. In 
this technique, particle size is reduced to enhance the performance of 
food, drug, and spices. Although, the degree of dissolution rate up-
gradation is highly needed to enhance the in vivo drug absorption for 
poorly soluble drug applicants are more prominent than that which 
can be given by micronization [11]. Thus, the further reduction in 
particle size of compounds to the range of nanometer must be 
considered as a strategy for up-gradation of the absorption of these 
drugs via oral route [12]. Numerous reports which have published 
recently have shown that the nanoparticles have the capabilities in up-
gradation of the oral absorption of poorly soluble drugs along with the 
betterment of other biopharmaceutical properties too (e. g., variable 
absorption in the fed vs. fasted state) [13-15]. 
. The nanoparticles are typically made 
utilizing the media milling method. The shear forces involved during 
the impaction of the milling procedure on the micron size drug crystals 
brings about nanometer-sized particles of the drug that can be 
dispersed in water and stabilized by the surface ligands acquainted 
with their surface [2]. Most extensively, nanomedicine is the way 
toward diagnosing, treating, preventing disease and traumatic injury, 
relieving pain and safeguarding in improving human health, utilizing 
molecular-level knowledge of the human body [3].  
Recent studies on solvency and dissolution improvement after 
nanosizing have reported variable results [16, 17]. The most widely 
recognized practice for the solubility assurance detailed depended on 
the separation by filtration to isolate non-dissolved nanoparticles from 
the solution utilizing the membrane filters of different pore sizes (0.1, 
0.22, and 0.45m pore size) [18-20]. A couple of reports have likewise 
demonstrated the utilization of molecular weight cut-off filters [21], 
dialysis bag method [22], centrifugation [23], and ultracentrifugation 
[24] for the separation of non-dissolved and dissolved nanocrystals 
while estimating solubility. Although, proof of adequate separation of 
non-dissolved and dissolved nanocrystals has been unclear. 
Determining precise solubility is a genuinely necessary instrument in 
the pre-formulation examination of any nanocrystalline particles of a 
poorly soluble compound. Nevertheless, the accurate measurement of 
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solvency during the drug molecule in the range of nanometer is a great 
challenge. Complicating this is the inclination of nanoparticles that stay 
suspended in the solution even after centrifugation [25]. Accordingly, 
the development of a technique for accurate solubility determination 
related with nanocrystals is one of the aims for current researchers.  
One of major disadvantage of nanocrystals includes instability 
during storage. Ostwald ripening alludes to a phenomenon that 
small particles steadily solubilise and settle on the larger particle 
surface after some time. It happens when the particle size in a 
dispersion system is heterogeneous and the dispersed phase has a 
limited solubility in the aqueous mediums, which, tragically, are the 
conditions much of the time experienced in pharmaceutical 
suspension. Ostwald ripening prompts the particle size development 
and physical instability of a dispersion system while storage; in this 
way, there is a solid requirement for anticipating this process. 
Surfactants and polymers are regularly utilized as stabilizers to 
defer separation and connection of drug molecules at the surface of 
dispersed particles. Polymers are accepted to be more powerful than 
little molecular weight surfactants since they will, in general, adhere 
to the nanocrystal surface less dynamically than surfactants. 
Another method for avoiding particle size growth is to formulate 
uniform nanocrystals, along these lines disposing of one of the 
conditions for Ostwald ripening. Advancing the process parameters, 
for example, a number of high-pressure homogenization cycles, 
speed of milling and time of milling can dispose of huge particles and 
acquire size distribution of narrow range. Handling 
nanosuspensions into solid products is another method of 
preventing dynamic changes in the medium and in this manner, 
Ostwald ripening can we eliminated [26]. The search criteria used 
for review of this paper were nanocrystals, nanosuspensions in 
various platforms like Pubmed, Science Direct, Scopus and Innovare 
Academic Sciences Etc.,  
The main aim of this paper is to furnish a brief overview on 
nanosuspension, it is expected that this review article will give 
coherent information on nanosuspension and stand as a starting 
step for further advancement of nanosuspension.  
Nanosuspensions 
Nanosuspensions are submicron colloidal scatterings of nanosized 
drug particles that are stabilized by surfactants [27]. 
Nanosuspension is helpful in enhancement of dissolvability of drugs 
that are least soluble in water and lipid media. This philosophy is 
important for molecules with poor solubility, poor permeability or 
both which represents a huge test for the formulators [28]. 
Nanosuspensions are liquid dispersion which contains solid drug 
nanoparticles that are stabilized by surfactant and/or polymer [29]. 
A nanosuspension not just illuminates the issues of least 
dissolvability and bioavailability yet, in addition, modifies the drug 
pharmacokinetics and that improves safety and viability of drugs. If 
there should arise an occurrence of drugs that are insoluble in both 
water and inorganic media as opposed to utilizing lipoid systems, 
nanosuspensions are utilized as a formulation strategy. 
Nanosuspension formulation strategy is most suitable for the 
molecules with high log P value, large dose and high melting point. 
The usage of nanotechnology to formulate least water dissolvable 
drugs as nanosuspension offers the opportunity to address the 
nature of the deficiency related with this class of drugs. 
Nanosuspension has been accounted to improve absorption and 
bioavailability, it may diminish the dose of the conventional oral 
dosage forms. Drug particle size reduction prompts an expansion in 
surface area and therefore in the rate of dissolution as portrayed by 
the Nernst-Brunner and Levich alteration of the Noyes-Whitney 
equation. Besides, enhancement in saturation dissolvability is 
proposed by particle size reduction because of an expanded 
dissolution pressure clarified by the Ostwald-Freundlich equation. 
An enhanced measure of amorphous drug fraction could initiate 
higher saturation dissolvability. In nanosuspension technology, the 
drug is kept up in the required crystalline state with decreased 
particle size, prompting an enhanced dissolution rate and as needs 
be improved bioavailability. Medications enclosed inside 
nanosuspensions exist in the pharmaceutically satisfactory 
crystalline or amorphous state [30]. There are two primary 
methodologies for the formulation of nanosuspension that are a 
bottom-up and top-down strategy. The bottom-up strategy involves 
solubilizing drug in a solvent and further addition of non-solvent to 
precipitate crystals. The top-down strategy depends on mechanical 
rubbing to furnish huge crystalline particles size less than about 400 
nm are justifiable for administration [29]. 
Benefits of nanosuspension technology for poorly soluble drugs 
1) Diminished particle size, enhanced drug dissolution rate, 
enhanced rate and extent of absorption, enhanced bioavailability of 
the drug, area under plasma versus time curve, peak drug level, 
onset of time, decreased variability and lowered fed/fasted impacts.  
2) Compounds that are insoluble in water and soluble in oil can be 
formulated as nanosuspension, then again, nanosuspension can be 
utilized with lipoid systems and effectively formulate compounds 
that are insoluble in both water and oil. 
3) Nanoparticles prolongs the contact time of drug by adhering on 
to the gastrointestinal mucosa thus increase its absorption. 
4) Nanosuspension has got many routes of administration such as 
parenteral, oral, dermal, ocular and pulmonary makes it most 
convenient.  
5) Nanosuspension of nanoparticles offers different favorable 
circumstances over conventional ocular dosage forms, incorporating 
lower in the measure of dose, upkeep of drug release over a delayed 
timeframe, decrease in systemic toxicity of drug, improved drug 
absorption because of longer residing time of nanoparticles on the 
surface of cornea, higher concentration of drug in the infected tissue, 
and suitability for inadequately water-soluble drugs, and smaller 
particles are preferred endured by patients over bigger particles, in 
this way, nanoparticles may speak to promising drug carriers for 
ophthalmic applications. 
6) Nanosuspension possess the least incidence of adverse reactions 
by the excipients. 
7) Nanosuspensions defeat delivery issues for the compounds by 
deterring the need to dissolve them and by keeping up the drug in a 
favoured crystalline state of size adequately little for pharmaceutical 
acceptability. 
8) Nanosuspension has got resistance to hydrolysis, oxidation and 
also posses’ increased physical stability to settling. 
9) Decreased administration quantities need for intramuscular, 
subcutaneous, and ophthalmic use. 
10) Last but not least, nanosuspensions can help out in passive 
targeting [31-33]. 
Formulation approaches of nanosuspension 
There are two strategies for the manufacturing of nanosuspensions, 
"Bottom-Up" and the "Top-Down" technologies. Traditional 
techniques for precipitation are classified "Base Up Technology". 
The "Top-Down Technologies" are the disintegration methods and 
are favoured over the precipitation methods. This incorporates 
High-Pressure Homogenization in water, Media Milling, High-
Pressure Homogenization in nonaqueous media finally, blends of 
Precipitation and High-Pressure Homogenization. 
The top-down technique can be further divided into two approaches 
homogenization and attrition wet media milling. 
Attrition wet media milling  
An active drug substance is scattered with an aqueous solution in 
which the stabilizers were pre-isolated, the surface of nanocrystals 
is exceptionally strong and has high surface vitality, and it should be 
stabilized by a single or mixture of stabilizers. Stabilizers can be 
ionic or stearic and can be used as a solitary and/or in a combination 
of polymeric as well as surfactant stabilizers. At that point, the 
solution is poured in the grinding chamber alongside spherical 
beads and balls while the globules are pivoted at rapid. It is believed 
that because of the attrition between molecules' surface and the 
surface of the globule, particle size reduction occurs; the globules 
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and balls serving as a milling media. Globules are available in 
different sizes and are of different materials, however, for the most 
part, are made of glass, zirconium oxide, or polymeric material. The 
sort of material the globules are made of is a critical factor as they 
can interface with the dynamic drug substance. Albeit costly, these 
Beads are the best option in contrast to keeping away from 
impurities in the last formulation [36]. The size of the beads has a 
direct relationship with the ideal range of particle size in the 
formulation of nanocrystals [37]. The standard length for 
conventional milling utilizing overhead stirring is somewhere close 
to 3h and 12h. Doubtlessly, these parameters can change from 
molecule to molecule. Milling should be stopped once the desired 
particle size range is achieved. The rotational speed of the milling 
media is too critical parameter. With the too moderate speed, the 
globules can't pivot proficiently and milling can't be performed 
precisely, and with the too quick speed, the equally rotating balls 
may stay at the upper surface of the media and milling is halted. 
With a systematic study by trial and error the formulator selects the 
stabilizers, as well as other milling parameters and optimizes them 
in order to achieve the required particle size range and stability. The 
final product characteristics can vary, depending on the amount of 
globules, the ratio of active drug substance to the amount of 
globules, the ratio of concentrations of active substance to the 
stabilizer, milling time, milling temperature as well as milling 
duration [38]. This technique is simple, inexpensive, and easily 
scalable. The only drawback associated with this technology is the 
contamination related to the beading material. That aside, several 
products have successfully reached the commercial level using this 
technology. Djordje Medarevic et al. formulated carvedilol 
nanosuspension by using wet media milling with help of hydroxyl 
propyl cellulose SL and sodium lauryl sulphate as stabilizers that 
resulted in stabilized formulation with enhanced dissolution rate 
[39]. Ligang Guo et al. used wet media milling to prepare 
andrographolide nanosuspension with non-ionic and ionic 
stabilizers resulted in nanosuspension having a particle size of about 
300 nm with no chemical degradation [40]. Chengying Shen et al. has 
prepared nitrofurazone nanosuspension by using wet media milling 
has shown better bioavailability via dermal route when compared to 
nitrofurazone marketed gel [41]. Song Huang et al. used wet milling 
to formulate nanosuspensions of efonidipine hydrochloride resulted 
in enhanced bioavailability [42]. 
 
 
Fig. 1: Schematic diagram of preparation methods of nanosuspension [34] 
 
 
Fig. 2: Top-down and bottom-up approach [35] 
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Fig. 3: Schematic representation of attrition wet media milling [43] 
 
High-pressure homogenization 
The fundamental guideline is high pressure that is 100–1500 bars. 
By this pressure, we can undoubtedly change over the micron size 
particle, into nanosize particle. Moreover, it at first needs the micron 
range particle that is<25 micrometer, with the goal that we need to 
get the example from the jet mill on the grounds that by utilizing jet 
mill we can decrease the particle size up to<25 micrometers. 
Furthermore, we can use the equipment for both batch and 
continuous operations. Capacity is also 40 ml to thousand litres. 
Here first, we need to change over the particles into the form of pre-
suspension. High pressure and high shear are because of collision of 
particles, the size of the particle will be diminished. Here, we need to 
add viscosity enhancers to build the viscosity of nanosuspension. In 
this method we need to majorly focus on the two parameters called 
pressure and homogenization cycles [44]. Hui wang et al. has 
formulated daidzein nanosuspension via high-pressure 
homogenization technique by using stearic and electrostatic 
stabilizers to have improved solubility and oral bioavailability [45]. 
Alptug Karakucuk et al. has prepared Ritonavir nanosuspension via 
high-pressure homogenization using microfluidizer with HPMC 3 
cps and sodium dodecyl sulfate as stabilizers resulted in improved 
oral bioavailability in fed state [46]. Emine Tashan et al. formulated 
the nanosuspension of ziprasidone by using microfluidizer resulted 
in increased aqueous solubility compared to a coarse powder and 
physical mixtures of drug [47]. Sumathi R et al. prepared polymeric 
nanosuspension of naringenin by utilizing high-pressure 
homogenization leaded in elevated dissolution rate and better 
stability [48]. 
 
 
Fig. 4: Schematic representation of high pressure 
homogenization [49] 
 
Bottom up approach 
Bottom up methodology is otherwise called precipitation technique. 
Precipitation has been connected for quite a long time to form 
submicron particles inside the most recent decade, particularly for 
the poorly soluble drugs. Normally, the drug is dissolved in a solvent 
firstly. At that point, this solution is blended with a miscible anti-
solvent with the help of surfactants. Fast addition of a drug solution 
to the anti-solvent (typically water) prompts unexpected super-
saturation of the drug in the blended solution and formation of 
ultrafine crystalline or amorphous drug solids. When setting up a 
stable suspension with the least particle size, a high nucleation rate 
however low growth rate is fundamental. The two rates are reliant 
majorly on temperature, where the optimum temperature for 
nucleation may lie beneath that for growth of crystal, which further 
permits temperature optimization [30]. Harsha Kathpalia et al. have 
prepared atovaquone nanosuspension by anti-solvent precipitation 
and pH based precipitation methods with the help of poloxamer, 
povidone and phospholipids that resulted in not only stability of 
suspension but also the dissolution rate of nanosuspension [50]. 
Aline Martins dos Santos et al. were used nanoprecipitation 
technique to obtain methotrexate nanosuspension which resulted in 
improved dissolution rate of methotrexate [51]. Mohammad H. 
Shariare et al. used the anti-solvent precipitation technique for the 
preparation of furosemide nanosuspension has increased relative 
bioavailability of about 2.3 folds than pure drug [52]. HE Suna et al. 
used an anti-solvent sonication-precipitation technique to prepare 
teniposide nanosuspension by using PVP as a stabilizer which resulted 
in physically and chemically stable suspension for atleast 10 d at 4°C 
[53]. Bibaswan Mishra et al. were used controlled precipitation 
ultrasonication method to prepare nanosuspensions of naproxen 
which has helped to overcome the problems of bioavailability [54]. 
Manishaanjane et al. prepared valsartan nanosuspension with help of 
nanoprecipitation technique showed better stability and elevated 
solubility [55]. Dekate S et al. used precipitation techniques to 
formulate curcumin nanosuspension that resulted in better in vitro 
dissolution rate than plain curcumin via oral route [56]. 
 
 
Fig. 5: Schematic representation of the precipitation method [34] 
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Emulsion diffusion method 
The emulsion can also be utilized as templates to create nanosuspension 
apart from drug delivery vehicles. The Drugs that are soluble in either or 
partially water-miscible solvent or volatile organic solvent can utilize the 
emulsions as a template. Such solvents can be utilized as the dispersed 
phase of the emulsion. Mixture of organic solvents stacked with the drug 
is dispersed in the aqueous phase containing appropriate surfactants 
along with stirring to result in an emulsion. The formed emulsion was 
additionally homogenized by high-pressure homogenization. After 
homogenization cycles, water has been added to dilute the emulsion, 
homogenized to diffuse organic solvent and convert the droplets into the 
solid particles. Since one particle is shaped in every emulsion droplet, it 
is conceivable to control the particle size of the nanosuspension by 
controlling the size of the emulsion optimizing the composition of 
surfactant which enhances the intake of organic phase and eventually 
loading of drug in the emulsion. Fundamentally methanol, ethanol, ethyl 
acetate chloroform are utilized as organic solvents [57-60]. 
Micro emulsion template 
This technique pursues mixture solvent or organic solvent loaded with 
the drug dispersed in an aqueous phase which contains an appropriate 
surfactant to result an emulsion. Further the organic phase was 
evaporated under the reduced pressure to make that the particles of 
drug precipitate quickly to give the nanosuspension which is later on 
stabilized by surfactants. Another method utilizes partially water 
miscible solvents, for example, butyl lactate, benzyl alcohol and triacetin 
as the dispersed phase rather than dangerous solvents [61]. 
Combination approach 
Combination strategy was created to defeat the issues of the top 
down and bottom up techniques. This technique is the combination 
of top down and bottom up techniques. This technology is the two 
stage process. Initial step is the pre-treatment process (bottom up) 
and second step is reduction of the particle size. In second step, high 
pressure homogenization is utilized. This procedure is also known 
as annealing. Annealing is the way toward converting the unstable 
matter into the stable form by single or rehashed use of energy, 
trailed by thermal relaxation. The nanocrystals formed utilizing 
combination technology has particle size underneath 200 nm.  
Applications of nanosuspension 
The applications of nanosuspensions had land marking history. 
Among these few applications are given below. 
Oral drug delivery 
Inadequate solubility, lacking disintegration, and deficient efficacy 
are the serious issue of oral route of drug administration. Because 
least size of particles and higher surface to volume ratio, oral 
nanosuspensions are remarkably used to build the rate of 
absorption and bioavailability of least dissolvable drugs [62]. If there 
should be an occurrence of azithromycin nanosuspensions, over 
65% of medication was seen to be dissolved in 5 h as appeared 
differently in relation to 20% of micronized drugs [63]. The 
nanosuspensions have major involvement in improved oral 
absorption, dose proportionality, and low inter subjected variability. 
By using standard manufacturing strategies, drug nanosuspensions 
can be basically joined into different dosage forms like fast melts, 
capsules and tablets. The nanosuspension of ketoprofen was 
adequately consolidated into pellets for the sustained release of the 
drug over the time of 24 h [64]. 
Parental drug delivery 
The present methodologies for parental delivery loaded micellar 
solutions, salt formation, solubilisation using co-solvents, cyclodextrin 
complexation, and all the more as of late vesicular frameworks for 
instance, liposomes and niosomes. In any case, these strategies have 
constrainments like solubilisation limit, parental acceptability, high 
manufacturing cost, to solve the above problems, the nanosuspension 
technology is used. nanosuspensions are administered through different 
parental routes, for example, intra-articular, intraperitoneal, 
intravenous, and so on also, nanosuspensions increment the viability of 
parenterally administered drugs. Paclitaxel nanosuspension was 
reported to have their predominance in diminishing the median tumour 
burden [2]. Clofazimine nanosuspension exhibited advancement in 
stability and also efficacy above the liposomal clofazimine in 
mycobacterium avium-infected female mice [65]. Rainbow et al. showed 
that intravenous nanosuspension of itraconazole enhanced the adequacy 
of antifungal action in rats relative to the solution formulation [66]. 
Pulmonary drug delivery 
For delivering via pulmonary, nanosuspensions can be nebulized 
through mechanical or ultrasonic nebulizers. Inside seeing fine 
particles, all aerosol droplets contain medicated nanoparticles. 
Budesonide Corticosteroid has been viably formulated as 
nanosuspension for delivery via pulmonary route [67]. Aqueous 
suspensions of the medication can be effectively nebulized and 
directed by pulmonary route as the particle size is practically low. 
Different sorts of nebulizers are accessible for the administration of 
liquid formulations. There are few deugs that have been effectively 
attempted with pulmonary route are ibuprofen, ketotifen, 
indomethacin, budesonide, doxorubicin, nifedipine, interleukin-2, 
itraconazole, p53 gene, leuprolide, etc [68]. 
Ocular drug delivery 
The tear fluid secreted from lachrymal gland has least drug 
dissolving capabilities. On the off chance that it is planned as 
nanoparticles its dissolvability and bioavailability will elevate [69]. 
Nanosuspension is used to deliver drugs via ocular route for the 
purpose of sustained release. Liang and co-workers formulated 
cloricromene nanosuspension for ocular delivery with help of 
eudragit. Examination indicated higher availability of drug in 
aqueous humor of rabbit eye. As such, nanosuspension offers a 
promising strategy for improving the bioavailability and shelf-life of 
the drug after the ophthalmic application [70]. 
Targeted drug delivery 
Nanosuspensions are suitable for targeting specific organs in 
perspective on their surface properties. Close by this, it is anything 
but difficult to adjust in vivo conduct by changing the stabilizer. The 
drug will be taken up by the mononuclear phagocytic system which 
allows region-specific delivery of the drug. This can be used for 
concentrating on anti-fungal, anti-mycobacterial, or anti-leishmanial 
drugs to macrophages if the pathogens suffer intracellularly [71]. 
Kayser prepared an aphidicolin nanosuspension that improved the 
targeting of drug to macrophages which were infected by 
leishmania. He expressed that the drug as nanosuspension had ec50 
of 0.003µg/ml, while the conventional form had 0.16µg/ml [72]. 
Scholer et al. depicted an increased targeting of drug to the brain in 
the treatment of toxoplasmic encephalitis by utilizing an atovaquone 
nanosuspension [73]. 
Transdermal drug delivery 
Nanocrystals are evolved greatly in the field of transdermal delivery of 
the drug to overcome the solubility issues of drugs, in this manner 
expanding the concentration gradient in between the formulation and 
the skin, subsequently, transdermal permeation of the drug [26]. Due 
to its nano size in nature it exhibit better permeability than micro-
sized particles. A transient stability test demonstrated that all 
nanosuspension remained sensibly stable at various temperatures. 
The Lutein nanocrystals had the option to penetrate through cellulose 
nitrate layers, utilized as an in vitro model of a penetration barrier, 14 
times superior to coarse powder. In any case, no permeation through 
pig ear skin was watched, which shows that the Lutein entering the 
skin stayed there because of the lipophilicity [74].  
Mucoadhesion of the nanoparticles 
A nanoparticle has got capabilities to adhere on the mucosal surface 
because of tiny nano sized particles. During initial stages adhesion of 
particle occur followed by its absorption. To elevate much higher 
contact period nanosuspension is formulated along hydrogels made 
from variety of mucoadhesive polymers. The adhesiveness of the 
nanosuspension enhances the bioavailability as well as improves 
targeting of the parasites continuing in the GIT. Bupravaquone 
Mucoadhesive Nanosuspensions have been accounted for to exhibit 
a favorable position in TRC Alpha Deficient mice tainted with 
Cryptosporidium Parvum Oocytes [75]. 
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Future perspectives 
While the plan of nanoparticulate formulations has turned out to be 
progressively refined, fundamentally and reasonably basic 
nanocrystals have a one of a kind favorable position as for the 
advancement of marketed products. Nanocrystals can enormously 
upgrade the saturation dissolvability and dissolution rate of least 
dissolvable drugs with basic technologies for production and 
components. The huge contact area of nanocrystals can take into 
consideration a more noteworthy communication with tissue or cell 
surfaces and upgrade drug absorption. A few oral nanocrystal 
products are accessible on the market and dermal and IV products 
are effectively investigated. Notwithstanding, the capability of 
nanocrystals has not been completely examined for various 
applications, for example, targeted or local drug delivery. 
Attachment with a ligand introduces a chance to convey 
nanocrystals in a target-specific manner. Notwithstanding, the 
present methods of nanocrystal production and alteration don't 
satisfactorily address the difficulties being developed of such 
products, and new ways to deal with engineer nanocrystals are 
unequivocally anticipated. 
CONCLUSION 
Nanocrystals can be adopted by all poorly soluble drugs to defeat 
their solubility and bioavailability issues. The reduction in particle 
size to nanometer range adds to the enhanced particle surface, 
curvature, saturation solubility, dissolution velocity and further 
reasonable bioavailability. Nanosuspensions are specific and 
economically conceivable way to deal with tackle the issues of 
hydrophobic drug, for example, poor solubility and poor 
bioavailability. For excessive large scale nanosuspensions 
production, high pressure homogenization and media milling 
technology have been viably used. Striking characteristics, similar to 
progress of dissolution velocity, enhanced saturation solubility, 
upgraded bioadhesivity, versatility in surface modification, and 
burden less postproduction processing have expanded the uses of 
nanosuspensions for different routes of administration. 
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